C4 Therapeutics (CCCC) announced robust financial results for the fourth quarter of 2025, highlighted by a 111.5% year-over-year revenue increase. The biotechnology firm achieved a significant clinical milestone as its lead drug candidate, cemsidomide, transitioned into a Phase 2 registrational trial for treating multiple myeloma. This advancement underscores the company's progress in its oncology pipeline and its focus on targeted protein degradation therapies. Financially, the company remains in a strong position with a cash balance of $297.1 million as of the end of the quarter. Management noted that this liquidity provides a stable operational runway extending into 2028, supporting ongoing research and development. The combination of clinical success and disciplined financial management has bolstered investor confidence in the company's long-term growth prospects.
Get AI-powered deep analysis for every story with a paid subscription
Upgrade for Analysis